These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 34059991)

  • 21. An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia.
    Charlton MR; Alam A; Shukla A; Dashtseren B; Lesmana CRA; Duger D; Payawal DA; Duy Cuong D; Jargalsaikhan G; Cua IHY; Sollano JD; Singh KR; Madan K; Win KM; Kyi KP; Tun KS; Salih M; Rastogi M; Saraf N; Thuy PTT; Hien PTD; Gani RA; Mohamed R; Tanwandee T; Piratvisuth T; Sukeepaisarnjaroen W; Naing W; Hashmi ZY
    J Gastroenterol; 2020 Sep; 55(9):811-823. PubMed ID: 32666200
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Brief Report: Effect of Antiretroviral Switch From Tenofovir Disoproxil fumarate to Tenofovir Alafenamide on Alanine Aminotransferase, Lipid Profiles, and Renal Function in HIV/HBV-Coinfected Individuals in a Nationwide Canadian Study.
    Sarowar A; Coffin CS; Fung S; Wong A; Doucette K; Truong D; Conway B; Haylock-Jacobs S; Ramji A; Hansen BE; Janssen HLA; Cooper C
    J Acquir Immune Defic Syndr; 2022 Dec; 91(4):368-372. PubMed ID: 36288543
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in preventing HBV vertical transmission of high maternal viral load.
    Li B; Liu Z; Liu X; Liu D; Duan M; Gu Y; Liu Q; Ma Q; Wei Y; Wang Y
    Hepatol Int; 2021 Oct; 15(5):1103-1108. PubMed ID: 34312798
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased spine bone density in patients with chronic hepatitis B switched to tenofovir alafenamide: A prospective, multinational study.
    Ogawa E; Jun DW; Toyoda H; Hsu YC; Yoon EL; Ahn SB; Yeh ML; Do S; Trinh HN; Takahashi H; Enomoto M; Kawada N; Yasuda S; Tseng CH; Kawashima K; Lee HA; Inoue K; Haga H; Do AT; Maeda M; Hoang JH; Cheung R; Ueno Y; Eguchi Y; Furusyo N; Yu ML; Tanaka Y; Nguyen MH
    Aliment Pharmacol Ther; 2024 Jan; 59(2):239-248. PubMed ID: 37882252
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B.
    Jeong S; Shin HP; Kim HI
    Intervirology; 2022; 65(2):94-103. PubMed ID: 34731856
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of switching to tenofovir alafenamide fumarate in patients with entecavir-treated chronic hepatitis B.
    Kumada T; Toyoda H; Yasuda S; Ito T; Tanaka J
    Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e898-e904. PubMed ID: 35048656
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Superiority of tenofovir alafenamide fumarate over entecavir for serum HBsAg level reduction in patients with chronic HBV infection: A 144-week outcome study after switching of the nucleos(t)ide analog.
    Uchida Y; Nakao M; Yamada S; Tsuji S; Uemura H; Kouyama JI; Naiki K; Sugawara K; Nakayama N; Imai Y; Tomiya T; Mochida S
    PLoS One; 2022; 17(2):e0262764. PubMed ID: 35180213
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Review article: switching patients with chronic hepatitis B to tenofovir alafenamide-a review of current data.
    Lim YS; Seto WK; Kurosaki M; Fung S; Kao JH; Hou J; Gordon SC; Flaherty JF; Yee LJ; Zhao Y; Agarwal K; Lampertico P
    Aliment Pharmacol Ther; 2022 Apr; 55(8):921-943. PubMed ID: 35178711
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First-line therapies for hepatitis B in the United States: A 3-year prospective and multicenter real-world study after approval of tenofovir alefenamide.
    Pan CQ; Afdhal NH; Ankoma-Sey V; Bae H; Curry MP; Dieterich D; Frazier L; Frick A; Hann HW; Kim WR; Kwo P; Milligan S; Tong MJ; Reddy KR
    Hepatol Commun; 2022 Aug; 6(8):1881-1894. PubMed ID: 35445803
    [TBL] [Abstract][Full Text] [Related]  

  • 30. No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection.
    Cathcart AL; Chan HL; Bhardwaj N; Liu Y; Marcellin P; Pan CQ; Shalimar ; Buti M; Cox S; Parhy B; Zhou E; Martin R; Chang S; Lin L; Flaherty JF; Kitrinos KM; Gaggar A; Izumi N; Lim YS
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30038044
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Converting from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Patients with Hepatitis B Following Liver Transplantation.
    Cheng CH; Hung HC; Lee JC; Wang YC; Wu TH; Lee CF; Wu TJ; Chou HS; Chan KM; Lee WC
    Ann Transplant; 2023 Apr; 28():e938731. PubMed ID: 37081752
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study.
    Lampertico P; Buti M; Fung S; Ahn SH; Chuang WL; Tak WY; Ramji A; Chen CY; Tam E; Bae H; Ma X; Flaherty JF; Gaggar A; Lau A; Liu Y; Wu G; Suri V; Tan SK; Subramanian GM; Trinh H; Yoon SK; Agarwal K; Lim YS; Chan HLY
    Lancet Gastroenterol Hepatol; 2020 May; 5(5):441-453. PubMed ID: 32087795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics.
    Hsu YC; Wei MT; Nguyen MH
    Expert Rev Gastroenterol Hepatol; 2017 Nov; 11(11):999-1008. PubMed ID: 28965428
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment-naïve chronic hepatitis B.
    Lim J; Choi WM; Shim JH; Lee D; Kim KM; Lim YS; Lee HC; Choi J
    Liver Int; 2022 Jul; 42(7):1517-1527. PubMed ID: 35343041
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis.
    Jeong J; Shin JW; Jung SW; Park EJ; Park NH
    Clin Mol Hepatol; 2022 Apr; 28(2):254-264. PubMed ID: 34959261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarate.
    Kaneko S; Kurosaki M; Tamaki N; Itakura J; Hayashi T; Kirino S; Osawa L; Watakabe K; Okada M; Wang W; Shimizu T; Higuchi M; Takaura K; Yasui Y; Tsuchiya K; Nakanishi H; Takahashi Y; Watanabe M; Izumi N
    J Gastroenterol Hepatol; 2019 Nov; 34(11):2004-2010. PubMed ID: 31017689
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tenofovir alafenamide (TAF) treatment of HBV, what are the unanswered questions?
    Viganò M; Loglio A; Grossi G; Lampertico P
    Expert Rev Anti Infect Ther; 2018 Feb; 16(2):153-161. PubMed ID: 29338458
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tenofovir alafenamide for the treatment of chronic hepatitis B virus infection.
    Abdul Basit S; Dawood A; Ryan J; Gish R
    Expert Rev Clin Pharmacol; 2017 Jul; 10(7):707-716. PubMed ID: 28460547
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness and Renal Safety of Tenofovir Alafenamide Fumarate among Chronic Hepatitis B Patients: Real-World Study.
    Farag MS; Fung S; Tam E; Doucette K; Wong A; Ramji A; Conway B; Cooper C; Tsoi K; Wong P; Sebastiani G; Brahmania M; Haylock-Jacobs S; Coffin CS; Hansen BE; Janssen HLA
    J Viral Hepat; 2021 Jun; 28(6):942-950. PubMed ID: 33749086
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    Buti M; Gane E; Seto WK; Chan HL; Chuang WL; Stepanova T; Hui AJ; Lim YS; Mehta R; Janssen HL; Acharya SK; Flaherty JF; Massetto B; Cathcart AL; Kim K; Gaggar A; Subramanian GM; McHutchison JG; Pan CQ; Brunetto M; Izumi N; Marcellin P;
    Lancet Gastroenterol Hepatol; 2016 Nov; 1(3):196-206. PubMed ID: 28404092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.